Q1 EPS Forecast for Spyre Therapeutics Reduced by Analyst

Spyre Therapeutics, Inc. (NASDAQ:SYRE) – Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for Spyre Therapeutics in a research note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.86) for the quarter, down from their prior forecast of ($0.84). Wedbush has a “Outperform” rating and a $45.00 price objective on the stock. The consensus estimate for Spyre Therapeutics’ current full-year earnings is ($4.79) per share. Wedbush also issued estimates for Spyre Therapeutics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.15) EPS, FY2026 earnings at ($2.83) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.98) EPS.

Other equities research analysts have also issued research reports about the company. Robert W. Baird lifted their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday. Guggenheim boosted their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the company a “buy” rating in a report on Friday, October 25th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $48.57.

Spyre Therapeutics Price Performance

Spyre Therapeutics stock opened at $31.27 on Friday. The firm has a market capitalization of $1.61 billion, a P/E ratio of -4.19 and a beta of 2.90. Spyre Therapeutics has a one year low of $8.75 and a one year high of $47.97. The business has a fifty day moving average price of $31.32 and a 200-day moving average price of $30.44.

Hedge Funds Weigh In On Spyre Therapeutics

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in Spyre Therapeutics in the second quarter valued at $130,000. EFG Asset Management North America Corp. acquired a new stake in Spyre Therapeutics in the 2nd quarter valued at about $869,000. Bank of New York Mellon Corp acquired a new stake in Spyre Therapeutics in the 2nd quarter valued at about $2,767,000. Rhumbline Advisers purchased a new stake in shares of Spyre Therapeutics in the 2nd quarter valued at approximately $1,220,000. Finally, TD Asset Management Inc purchased a new stake in shares of Spyre Therapeutics in the 2nd quarter valued at approximately $827,000. Institutional investors own 80.39% of the company’s stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).